Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;16(19-20):1067-1091.
doi: 10.1080/17576180.2024.2411925. Epub 2024 Nov 14.

Harmonization of Vaccine Ligand Binding Assays Validation

Francis Dessy  1 , Ivo Sonderegger  2 , Leslie Wagner  3 , Alessandra Buoninfante  4 , Meenu Wadhwa  5 , Joseph Agnes  6 , Anastasia Aksyuk  7 , Angelique Baclin  1 , Marie Bonhomme  8 , Shane Cloney-Clark  9 , Bart Corsaro  10 , João Tavares Neto  11 , Louis Fries  9 , Luc Gagnon  12 , Fabio Garofolo  13 , Peter Giardina  14 , Tina Green  8 , Nuria Guimera  15 , Shannon Harris  16 , Roy Helmy  17 , James Huleatt  18 , Akiko Ishii-Watabe  19 , Ralf Jaeger  20 , Dewal Jani  21 , Sarah Janssen  15 , Lisa Kierstead  8 , Karen Makar  22 , Jean-Claude Marshall  23 , Christian Mayer  24 , Dulcyane Neiva Mendes  11 , Rocio Murphy  25 , Sankeetha Nadarajah  26 , Katrina Nolan  17 , Joyce Plested  9 , Ingrid Scully  14 , Therese Solstad  27 , Jeroen Stoop  15 , Charles Tan  28 , Thorsten Verch  17 , Deidre Wilkins  7 , Arron Xu  29 , Lingyi Zheng  23 , Mingzhu Zhu  9
Affiliations

Harmonization of Vaccine Ligand Binding Assays Validation

Francis Dessy et al. Bioanalysis. 2024.

Abstract

The urgency and importance of organizing a global effort to harmonize clinical assay validation specific to the vaccine industry was identified during the drafting of the 2020 White Paper in Bioanalysis due to the lack of clarity and regulatory guidance/guidelines in vaccine immunoassay validation. Indeed, the Workshop on Recent Issues in Bioanalysis (WRIB) issues the White Paper in Bioanalysis yearly, which is one of the high-profile articles of the Bioanalysis Journal focused on detailed discussions and recommendations on vaccine assay validation. Since 2017, participation in the WRIB working groups by vaccine assay validation experts and regulators has rapidly increased due to its unique format where industry leaders and regulators can meet and exchange ideas on topics of interest to both groups. In early 2021, Vaccine manufacturers approached WRIB for sponsoring/supporting the authorship and publication of an overarching vaccine assay validation document based on the 2017-2020 discussions and consensus starting from immunogenicity assays first and followed by future papers on molecular and cell-based assay validation. Using industry and WRIB vaccine network, a vaccine immunogenicity assay validation working group was assembled consisting of 16 companies. The work on the first white paper started officially in April 2021 focusing on Vaccine LBA Validation (Part 1), and the drafting of Vaccine LBA Development (Part 2) and Vaccine LBA Monitoring & Transfer (Part 3) are presently ongoing and expected to be published shortly after this paper. Moreover, recommendations on Vaccine Cell-Based Assays Validation (ELISpot and Flow cytometry) and Vaccine Molecular Assays Validation (PCR, NGS, NanoString) are also on the WRIB publications agenda and the drafting is planned to start in mid-2024. For too long, vaccine scientists have not had a clear validation guidance for clinical vaccine immunogenicity assays. We hope that this common effort will help close this regulatory gap.

Keywords: LBA; WRIB; bioanalysis; biomarkers; immunogenicity; vaccine; validation.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Corsaro B, Yang T-Y, Murphy R, et al. . 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis. 2021;13(6):415–463. doi:10.4155/bio-2021-0007 - DOI - PubMed
    1. Piccoli S, Mehta D, Vitaliti A, et al. . 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62). Bioanalysis. 2019;11(24):2207–2244. doi:10.4155/bio-2019-0271 - DOI - PubMed
    1. Loo L, Harris S, Milton M, et al. . 2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization). Bioanalysis. 2022;14(11):737–793. doi:10.4155/bio-2022-0081 - DOI - PubMed
    1. Sumner G, Keller S, Huleatt J, et al. . 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 - Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization. Bioanalysis. 2023;15(15):861–903. doi:10.4155/bio-2023-0151 - DOI - PubMed
    1. Pan L, Mora J, Walravens K, et al. . 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach). Bioanalysis. 2023;15(14):773–814. doi:10.4155/bio-2023-0135 - DOI - PubMed

LinkOut - more resources